Role of gamma-delta T-cells in cancer. Another opening door to immunotherapy

• Published in: Clinical & translational oncology Vol. 14; no. 12; pp. 891 - 895
• Main Authors: Marquez-Medina, Diego, Salla-Fortuny, Joel, Salud-Salvia, Antonieta
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01-12-2012
• Subjects: Clinical Trials as Topic; Educational Series – Red Series; Humans; Immunotherapy - methods; Medicine; Medicine & Public Health; Neoplasms - immunology; Neoplasms - therapy; Oncology; Receptors, Antigen, T-Cell, gamma-delta - immunology; T-Lymphocytes - immunology; Immune therapy; Zoledronic acid; Gamma-delta T-cells; Non-small cell lung cancer; Solid malignancies
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-012-0935-7

The gamma-delta (γδ) T-cells are a subset of T-lymphocytes characterized by the presence of a surface antigen recognition complex type 2. Those γδ T-cells represent 2–5 % of peripheral T-cells only, but they are common in organs and mucosae, acting as a first defense system in the entries to the organism. The γδ T-cells take part on immune response by direct cytolysis, development of memory phenotypes, and modulation of immune cells, and they have been implied in autoimmune disorders, immune deficiencies, infections, and tumor diseases. We reported the role of γδ T-cells in oncology, focusing in their potential applications for cancer treatment. Experimental designs and clinical trials in the treatment of solid malignancies are extensively reviewed.